Driver mutations promote initiation and progression of cancer. Pharmacological treatment
can inhibit the action of the mutant protein; however, drug resistance almost invariably …

A major obstacle in the treatment of acute myeloid leukemia (AML) is refractory disease or
relapse after achieving remission. The latter arises from a few therapy-resistant cells within …

In mammals, hematopoietic stem cells (HSCs) engage in hematopoiesis throughout adult
life within the bone marrow, where they produce the mature cells necessary to maintain …

While the understanding of the genomic aberrations that underpin chronic and acute
myeloid leukaemia (CML and AML) has allowed the development of therapies for these …

Metabolism has been studied mainly in cultured cells or at the level of whole tissues or
whole organisms in vivo. Consequently, our understanding of metabolic heterogeneity …

Malignant stem cells have long been considered a key therapeutic target in leukemia.
Therapeutic strategies designed to target the fundamental biology of leukemia stem cells …

The skeleton is diverse in its functions, which include mechanical support, movement, blood
cell production, mineral storage and endocrine regulation. This multifaceted role is achieved …

Despite an increasing arsenal of anticancer therapies, many patients continue to have poor
outcomes due to the therapeutic failures and tumor relapses. Indeed, the clinical efficacy of …

Tissue function depends on cellular organization. While the properties of individual cells are
increasingly being deciphered using powerful single-cell sequencing technologies …

Our study details the stepwise evolution of gilteritinib resistance in FLT3-mutated acute
myeloid leukemia (AML). Early resistance is mediated by the bone marrow …